$OREX Orexigen Remains Stuck in a Range: Potential Break Upward
publication date: Nov 30, 2010
Written by Bill Rusnak. Orexigen Therapeutics, Inc. (NASDAQ:OREX), a biopharmaceutical company that is near an Endocrinologic and Metabolic Drugs Advisory Committee meeting announcement for its product, Contrave, has traders at a stand-still.
Sorry this page is available to subscribers only. If you're not a subscriber why not join today?
You can also sign up for our 100% FREE Newsletter to stay current on public webinars, special offers, and news alerts: